This book is the first text to provide a comprehensive assessment of the application of fundamental principles of dissolution and drug release testing to poorly soluble compounds and formulations. Such drug products are, vis-a-vis their physical and chemical properties, inherently incompatible with aqueous dissolution. However, dissolution methods are required for product development and selection, as well as for the fulfillment of regulatory obligations with respect to biopharmaceutical assessment and product quality understanding. The percentage of poorly soluble drugs, defined in classes 2 and 4 of the Biopharmaceutics Classification System (BCS), has significantly increased in the modern pharmaceutical development pipeline. This book provides a thorough exposition of general method development strategies for such drugs, including instrumentation and media selection, the use of compendial and non-compendial techniques in product development, and phase-appropriate approaches to dissolution development. Emerging topics in the field of dissolution are also discussed, including biorelevant and biphasic dissolution, the use on enzymes in dissolution testing, dissolution of suspensions, and drug release of non-oral products. Of particular interest to the industrial pharmaceutical professional, a brief overview of the formulation and solubilization techniques employed in the development of BCS class 2 and 4 drugs to overcome solubility challenges is provided and is complemented by a collection of chapters that survey the approaches and considerations in developing dissolution methodologies for enabling drug delivery technologies, including nanosuspensions, lipid-based formulations, and stabilized amorphous drug formulations.
Gregory K. Webster is a senior principal research scientist with AbbVie Inc.'s Global Analytical Research and Development. He obtained his BS in chemistry from St. Xavier College, USA, MS in analytical chemistry from Governors State University, USA, and PhD in analytical chemistry from Northern Illinois University. Dr. Webster's industrial career spans an employment history with several major pharmaceutical companies. His first book with Pan Stanford Publishing, Supercritical Fluid Chromatography: Advances and Applications in Pharmaceutical Analysis, was published in 2014.
Robert G. Bell is president of Drug and Biotechnology Development LLC, USA, a consultancy to the pharmaceutical industry and academia for biological, drug, and device development. He received his education from the University of Florida and has worked with the pharmaceutical industry for over 30 years. Dr. Bell is adjunct faculty at Virginia Commonwealth University and the University of Florida College of Pharmacy and a member of the Council of Experts, General Chapters-Biological Analysis for United States Pharmacopeia.
J. Derek Jackson is director of Analytical Development at Flexion Therapeutics Inc, USA. He earned his BS and MA in chemistry from the College of William and Mary in Virginia. Derek has been engaged in all stages of pharmaceutical discovery, research, and development for 20 years, in both large pharma and small- to midcap biotech companies.
- The Modern Pharmaceutical Development Challenge: BCS Class II and IV Drugs
Gregory K. Webster, Robert G. Bell, and J. Derek Jackson
- Solubility Determinations for Pharmaceutical API
Kofi Asare-Addo and Barbara R. Conway
- Use of Surfactants in Dissolution Testing
- Intrinsic Dissolution Evaluation of Poorly Soluble Drugs
Michele Georges Issa and Humberto Gomes Ferraz
- Oral Delivery of Poorly Soluble Drugs
Dev Prasad, Akash Jain, and Sudhakar Garad
- A Staged Approach to Pharmaceutical Dissolution Testing
Gregory K. Webster, Xi Shao, and Paul D. Curry, Jr.
- Development and Application of in vitro Two-Phase Dissolution Method for Poorly Water-Soluble Drugs
Ping Gao, Yi Shi, and Jonathan M. Miller
- The Use of Apparatus 3 in Dissolution Testing of Poorly Soluble Drug Formulations
G. Bryan Crist
9. Use of Apparatus 4 in Dissolution Testing, Including Sparingly and Poorly Soluble Drugs
Rajan Jog, Geoffrey N. Grove, and Diane J. Burgess
- Dissolution of Nanoparticle Drug Formulations
- Dissolution of Lipid-Based Drug Formulations
Stephen M. Cafiero
- Dissolution of Stabilized Amorphous Drug Formulations
Justin R. Hughey
- Dissolution of Pharmaceutical Suspensions
Beverly Nickerson, Michele Xuemei Guo, Kenneth J. Norris, and Ling Zhang
- Dissolution Testing of Poorly Soluble Drugs: "Biorelevant Dissolution"
Mark McAllister and Irena Tomaszewska
- Clinically Relevant Dissolution for Low-Solubility Immediate-Release Products
Paul A. Dickinson, Talia Flanagan, David Holt, and Paul W. Stott
- The QbD Approach to Method Development and Validation for Dissolution Testing
Alger D. Salt
- Regulatory Considerations in Dissolution and Drug Release of BCS Class II and IV Compounds
Robert G. Bell and Laila Kott
- Dissolution of Liquid-Filled Capsules Based Formulations
Rampurna Prasad Gullapalli
- Current and Emerging Non-compendial Methods for Dissolution Testing
Namita Tipnis and Diane J. Burgess
"Even those who have been developing dissolution methods for years will find valuable information, since this text goes well beyond the basics of dissolution development for poorly soluble drugs. . . . The book walks through the lifecycle of a dissolution method for a poorly soluble compound, starting with solubility and intrinsic dissolution, including use of surfactants, has chapters that address several of the strategies used for formulation development and the staged approach to development of dissolution methods, provides chapters on alternatives to the traditional USP dissolution Apparatus 1 and 2, including Apparatus 3 and 4 and noncompendial approaches, then moves to some of the most interesting information describing biorelevant dissolution, clinically relevant dissolution, QbD approaches, and regulatory considerations. . . . Overall, this is a book that I strongly recommend for everyone involved in dissolution method development. It goes into much greater detail than similar texts and provides practical information that will prove helpful in addressing the concepts presented, both from a scientific and a regulatory perspective."
--Dissolution Technologies, February 2017